Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 7/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168739 | 0.85 | GCK (0.34) | CNR2PIK3CDCNR1GCKRIPK1 | |
| SCHEMBL4161910 | 0.83 | METAP1 (0.42) | POLBHPGDPKMMEN1HTT | |
| SCHEMBL14347430 | 0.76 | CNR2 (0.33) | CNR2CNR1 | |
| SCHEMBL14374851 | 0.75 | CNR2 (0.32) | CNR2CNR1POLBHPGDPKM | |
| SCHEMBL2201094 | 0.72 | PIK3CD (0.35) | PIK3CD | |
| SCHEMBL4166505 | 0.71 | HPGD (0.36) | CNR2PIK3CDCNR1POLBHPGD | |
| SCHEMBL13727465 | 0.69 | LIPA (0.42) | CNR2PIK3CDCNR1POLBHPGD | |
| SCHEMBL12091439 | 0.68 | PIK3CD (0.39) | PIK3CDGCK | |
| SCHEMBL4170837 | 0.68 | POLB (0.41) | CNR2PIK3CDCNR1POLBHPGD | |
| SCHEMBL105008 | 0.68 | PIK3CD (0.47) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236841-B2 | Fused heterocycle derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-20090239853-A1 | Fused heterocycle derivative | KYOWA KIRIN CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-2070927-A1 | FUSED HETEROCYCLIC DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239853-A1 | Fused heterocycle derivative | NR5A2, CBR3, NR3C2 | CNR2 173/4885PIK3CD 3777/4885CNR1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.